Sanuwave Health (NASDAQ:SNWV) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Sanuwave Health's rating has been upgraded from "buy" to "strong-buy" by analysts at Wall Street Zen, indicating increased confidence in the stock.
• Roth Capital raised its price target for Sanuwave Health from $54.00 to $55.00, with the consensus rating currently at "Buy."
• In Q2, Sanuwave Health reported earnings of $0.01 per share, surpassing estimates, and saw institutional ownership increase, reflecting strong investor interest.

Wall Street Zen upgraded shares of Sanuwave Health (NASDAQ:SNWV - Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

Separately, Roth Capital raised their target price on shares of Sanuwave Health from $54.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Sanuwave Health currently has an average rating of "Buy" and a consensus target price of $55.00.

Sanuwave Health Stock Performance

NASDAQ SNWV traded down $0.80 during trading on Friday, reaching $41.64. 34,353 shares of the company's stock traded hands, compared to its average volume of 48,216. The company has a 50 day simple moving average of $36.93. Sanuwave Health has a 12-month low of $5.21 and a 12-month high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The business had revenue of $10.16 million for the quarter, compared to analysts' expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Insider Activity

In other news, COO Peter Stegagno sold 1,862 shares of Sanuwave Health stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $27.71, for a total value of $51,596.02. Following the transaction, the chief operating officer owned 2,032 shares of the company's stock, valued at $56,306.72. The trade was a 47.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 14.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of Sanuwave Health in the 2nd quarter worth approximately $26,000. Strategic Investment Solutions Inc. IL acquired a new stake in Sanuwave Health in the 1st quarter worth approximately $47,000. BNP Paribas Financial Markets acquired a new stake in Sanuwave Health in the 2nd quarter worth approximately $46,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sanuwave Health in the 2nd quarter worth approximately $52,000. Finally, New York State Common Retirement Fund acquired a new stake in Sanuwave Health in the 2nd quarter worth approximately $102,000. Hedge funds and other institutional investors own 42.53% of the company's stock.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.